Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 476 first isolates · MED-A · Febrile UTI / pyelonephritis · 2025-09-28 → 2026-09-27
Internal medicine ANo single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
piperacillin-tazobactam 79 % (75 %–82 %)
Best two-drug combination: vancomycin + piperacillin-tazobactam covers 93 % (90 %–95 %)
Take cultures before treatment; consider a combination and discuss with infectious
diseases if the patient is severely ill.
Not covered: Enterococcus faecalis (11 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
⚠ CPE case in the ward: carbapenem resistance possible
83 %
81 %
n = 31
Most likely organisms for this profile
Escherichia coli
55 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
11 %
Proteus mirabilis
6 %
Citrobacter freundii
4 %
Pseudomonas aeruginosa
4 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.